The National Lipid Association (NLA) has released updated guidance for clinicians on identifying patients for which proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor therapy would provide reasonable value. Currently, two PCSK9 therapies have been approved by the Food and Drug Administration. Alirocumab is indicated as an adjunct to diet, alone or in combination with…
The FDA has approved Fragmin, a low molecular weight heparin, for the treatment of symptomatic venous thromboembolism to reduce the recurrence of VTE in pediatric patients 1 month of age and older.
Risks reduced for total cardiovascular disease events, CVD death, coronary heart disease, and stroke
A first-in-class artificial intelligence-based solution that enables healthcare professionals to detect heart murmurs on a personal mobile device has received clearance from the FDA.
AliveCor announced that the FDA has cleared a new iteration of their KardiaMobile device, the KardiaMobile 6L, the first 6-lead personal electrocardiogram (ECG) device.
The FDA has approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
According to the results of a recent study, the duration of antibiotic exposure in women during middle and older adulthood may significantly impact the risk of future cardiovascular (CVD) events. The study aimed to determine the association between both the duration of antibiotic exposure as well as the period of antibiotic use and subsequent…
The FDA has approved Praluent (alirocumab; Sanofi and Regeneron), a PCSK9 inhibitor, to reduce the risk of myocardial infarction (MI), stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease.
The Food and Drug Administration (FDA) has cleared KardiaMobile (AliveCor), a personal ECG device, for use in detecting bradycardia and tachycardia.
A recently published report describes the case of a 31-year-old African American female who experienced psychiatric symptoms after her dose of sacubitril/valsartan was increased.
